Investor Conference Call

Transcription

1 Investor Conference Call Q Results October 30, 2014 / Marijn Dekkers, CEO Page 1 Q Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 2 Q Investor Conference Call Marijn Dekkers

2 Q Operational Strength and Strategic Focus on Life Sciences Strong organic top line growth in all subgroups Underlying EBITDA improvement negatively impacted by minus 80m FX effect Business portfolio significantly strengthened and focused Planned stock-market listing of MaterialScience announced Merck & Co. CC acquisition & sgc pharma collaboration closed Divestiture of Interventional business closed Full-year group guidance 2014 raised Page 3 Q Investor Conference Call Marijn Dekkers CC: Consumer Care Q Strong Organic Growth / Performance Impacted By FX in million % currency & portfolio adj. EBIT in million EBITDA adjusted* in million Core EPS in 9,643 10,187 1,221 1,376 1,984 2, % +13% +1% +6% Page 4 Q Investor Conference Call Marijn Dekkers

3 Q Regional Performance: Growth In All Regions In million, % yoy Fx adjusted Group by Region Emerging Markets USA +8% 21% Emerging Markets¹ +12% +11% ~1, % ~1,500 41% +12% 3 Western Europe +2% 8% Others² +4% ~600 +4% ~400 Group 10,187m; +7% Emerging Asia³ Latin America Eastern Europe Africa & Middle East Page 5 Q Investor Conference Call Marijn Dekkers ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia w/o Japan, Australia, New Zealand Q Cash Flow And Net Debt Development Cash Flow in million, Net Debt in billion Cash Flow Net Debt Development GCF NCF Investments ofcf bn 8.5 1,492 1, ,270 y-o-y +9% +5% +6% +5% June 30, 2014 Sep 30, 2014 Page 6 Q Investor Conference Call Marijn Dekkers

4 Q HealthCare: Continued Dynamic Growth Driven by Pharma & Consumer Care Consumer Health (+2%) 36% Pharma +8% (+1) 1,921 3,039 1,392 1,402 +1% 1,048 1,037-1% HealthCare 4,960m; +5% (+7%) Price +1% Volume +6% Fx -2% Portfolio Page 7 Q Investor Conference Call Marijn Dekkers Q Pharma: Launch Products Continue to Drive Growth Launch products % % Pharmaceuticals 3,039m; +8% (+1) Page 8 Q Investor Conference Call Marijn Dekkers

5 Q Consumer Health: Continued Strong Consumer Care and Animal Health Business Animal Health +3% (+4%) % 585 Medical Care -5% (-4%) Consumer Care +2% (+6%) 1, % % Consumer Health 1,921m; (+2%) Page 9 Q Investor Conference Call Marijn Dekkers Q CropScience: Continued Strong Performance in North / Latin America Environmental Science +6% (+8%) Crop Protection +1 (+12%) ,650 Seeds +93% (+96%) CropScience 1,929m; +13% (+15%) % % Price +3% Volume +11% Fx -2% Portfolio Page 10 Q Investor Conference Call Marijn Dekkers

6 Q MaterialScience: Volumes Driven by Increased Demand Polycarbonates +8% (+8%) 726 1,652 Polyurethanes +5% (+6%) CAS** +3% (+5%) % IO*** -9% (-9%) 155 MaterialScience 3,036m; +5% (+5%) Price -1% Volume +6% Fx Portfolio Page 11 Q Investor Conference Call Marijn Dekkers **CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations Q Full-Year Group Guidance Raised Fx and portfolio adjusted, EBITDA before special items E as of Feb 14 (Avg. Fx rates Q4 13) 2014E* (Spot Fx rates as of Sep 30, 2014 for Q4 14) 40.2bn ~5% to ~ 41-42bn (neg. FX effect approx. -2%) ~6% to ~ 42bn (neg. FX effect approx. -3%) adj. EBITDA 8.4bn low- to mid-singledigit % increase mid-single-digit % increase (neg. FX effect approx. -5%) (neg. FX effect approx. -5%) core EPS 5.61 mid-single-digit % increase (neg. FX effect approx. -6%) mid- to high-singledigit % increase (neg. FX effect approx. -7%) Page 12 Q Investor Conference Call Marijn Dekkers Outlook depends on specific planning assumptions as detailed in the Annual Report *including Merck & Co. Consumer Care business from Oct 1, 2014

7 Investor Conference Call Q Results October 30, 2014 / Marijn Dekkers, CEO Page 13 Q Investor Conference Call Marijn Dekkers